Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PEMBROCABOSARC
2023-509496-16-00Phase 2Authorised
- Sponsor
- Institut Bergonié
- Start
- Oct 2024
- Modality
- Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes, Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of pembrolizumab and cabozantinib in Malignant Fibrous Histiocytoma (MFH), osteosarcoma (OS) and Ewing sarcoma, sponsored by Institut Bergonié. Primary endpoints: 6-month non-progression rate, Non-progression definition and 2 more. Planned start Oct 2024; status: authorised.
02
Drugs
pembrolizumabcabozantinib
03
Conditions
Malignant Fibrous Histiocytoma (MFH)osteosarcoma (OS)Ewing sarcoma
Beyond the preview
Go deeper on 2023-509496-16-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2023-509496-16-00.